国: シンガポール
言語: 英語
ソース: HSA (Health Sciences Authority)
CLOBETASOL PROPIONATE
GLAXOSMITHKLINE PTE LTD
D07AD01
0.05% w/w
CREAM
CLOBETASOL PROPIONATE 0.05% w/w
TOPICAL
Prescription Only
GLAXO WELLCOME OPERATIONS
ACTIVE
1990-07-12
CONFIDENTIAL DERMOVATE™ _CLOBETASOL_ PROPIONATE QUALITATIVE AND QUANTITATIVE COMPOSITION _DERMOVATE_ Cream and Ointment contains _Clobetasol _propionate 0.05 % w/w. PHARMACEUTICAL FORM Cream and Ointment. CLINICAL PARTICULARS INDICATIONS - Psoriasis (excluding widespread plaque psoriasis) - Recalcitrant eczemas - Lichen planus - Discoid lupus erythematosus - Other skin conditions which do not respond satisfactorily to less potent steroids DOSAGE AND ADMINISTRATION_ _ Apply sparingly to the affected area once or twice daily. Therapy should be discontinued when control is achieved. Treatment should not be continued for more than four weeks without the patient’s condition being reviewed. Repeated short courses of _DERMOVATE_ may be used to control exacerbations. If continuous steroid treatment is necessary, a less potent preparation should be used. In very resistant lesions, especially where there is hyperkeratosis, the anti-inflammatory effect of _DERMOVATE_ can be enhanced, if necessary, by occluding the treatment area with polythene film. Overnight occlusion only is usually adequate to bring about a satisfactory response. Thereafter improvement can usually be maintained by application without occlusion. CHILDREN DERMOVATE is contraindicated in children under one year of age. Children are more likely to develop local and systemic side effects of topical corticosteroids and, in general, require shorter courses and less potent agents than adults. Singapore proposed PI_ clean CONFIDENTIAL Care should be taken when using DERMOVATE to ensure the amount applied is the minimum that provides therapeutic benefit. ELDERLY The greater frequency of decreased hepatic or renal function in the elderly may delay elimination if systemic absorption occurs. Therefore the minimum q 完全なドキュメントを読む
DERMOVATE CLOBETASOL PROPIONATE Dermovate Cream is a smooth white to off-white cream. Dermovate Ointment is a smooth white to off-white translucent ointment. QUALITATIVE AND QUANTITATIVE COMPOSITION _DERMOVATE_ Cream and Ointment contains clobetasol_ _propionate 0.05 % w/w. CLINICAL INFORMATION INDICATIONS - Psoriasis (excluding widespread plaque psoriasis) - Recalcitrant eczemas - Lichen planus - Discoid lupus erythematosus - Other skin conditions which do not respond satisfactorily to less potent steroids DOSAGE AND ADMINISTRATION_ _ Pharmaceutical form: Cream and Ointment Apply sparingly to the affected area once or twice daily. Therapy should be discontinued when control is achieved. Treatment should not be continued for more than four weeks without the patient’s condition being reviewed. Repeated short courses of _DERMOVATE_ may be used to control exacerbations. If continuous steroid treatment is necessary, a less potent preparation should be used. In very resistant lesions, especially where there is hyperkeratosis, the anti-inflammatory effect of _DERMOVATE_ can be enhanced, if necessary, by occluding the treatment area with polythene film. Overnight occlusion only is usually adequate to bring about a satisfactory response. Thereafter improvement can usually be maintained by application without occlusion. CHILDREN _DERMOVATE_ is contraindicated in children under one year of age. Children are more likely to develop local and systemic side effects of topical corticosteroids and, in general, require shorter courses and less potent agents than adults. Care should be taken when using _DERMOVATE_ to ensure the amount applied is the minimum that provides therapeutic benefit. ELDERLY The greater frequency of decreased hepatic or renal function in the elderly may delay elimination if systemic absorption occurs. Therefore, the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit. RENAL/HEPATIC IMPAIRMENT In case of systemic absorption (when application is over a large su 完全なドキュメントを読む